Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
ConditionRetinopathy of Prematurity (ROP)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorWang Yusheng
About this trial
Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)
Eligibility criteria
Qualifiers
Preterm infants with less than or equal to 2000 grams of birth weight or less than or equal to 32 weeks of gestational age
Bilateral type 1 ROP with one of the following retinal findings in each eye
Zone I, stage 1+, 2+, 3+/- disease, or
Zone II, stage 2+, 3+, disease, or
Disqualifiers
Preterm infants with stage 4 or 5 ROP in one or both eyes
Have received any previous surgical or nonsurgical treatment for ROP, including laser photocoagulation, anti-VEGF therapy, vitrectomy
Have been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)
Have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer
Trial design
Treatments tested in this trial
- Conbercept
Treatment groups
146 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wang Yusheng
Lead sponsor
Xijing Hospital
Sponsor institution
Source ClinicalTrials.gov